You can narrow down the results using the filters
-
Safety and Efficacy of FSD202 for the treatment of chronic pain associated with idiopathic MCAS (MCAD)
Expand descriptionThis study is a randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of FSD202 in adult participants with musculoskeletal nociplastic pain associated with MCAS. The study will be conducted as a decentralized clinical trial. Participants who meet the eligibility criteria will be randomized remotely, via the IVRS system, to receive 300 mg FSD202 or a placebo orally twice daily for 56 days in a ratio of 2:1. The study design consists of up to 17 days screening period, up to 4 days for randomization and initial delivery of IP to participant’s home, a 56-day treatment period, and a 7-day follow-up period. Each participant will participate in the trial for up to 84 days. 1. The study aimes to evaluate the analgesic efficacy of FSD202 compared to placebo in participants with chronic widespread musculoskeletal nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome/ Disorder (MCAS/MCAD).
-
Prescriptions for Connection-A Social Prescribing Approach to Healthy Ageing in Adelaide's North
Expand descriptionThis interventional pilot and feasibility study will use a multiphase mixed methods process and outcomes evaluation, reported in line with the CONSORT checklist. Prescriptions for Connection, a social prescribing program, will be co-designed and implemented in six Australian primary care practices and three council areas. Implementation outcomes will be evaluated using the Reach, Effectiveness, Adoption, Implementation and Maintenance Framework. Qualitative data collection, via focus groups for health and social care providers and interviews for older people, will be based on the Consolidated Framework for Implementation Research to explore barriers and facilitators, and explain outcomes.
-
PRE-TREAT: A clinical trial exploring if a combination inhaler prevents early lung changes from developing into full chronic obstructive pulmonary disease (COPD).
Expand descriptionChronic Obstructive Pulmonary Disease (COPD) is a severe condition causing millions of deaths annually, with late diagnosis and progressive lung damage making current treatments only symptomatic. The trial focuses on the pre-COPD phase, a critical period when lung function begins to decline but before permanent damage occurs, offering an opportunity for intervention. Inhaled Triple Therapy (fluticasone furoate, umeclidinium, and vilanterol) may slow lung function decline and prevent progression to COPD. This double-blind, randomized, placebo-controlled trial will involve 500 participants from the Tasmanian Longitudinal Health Study (TAHS) to evaluate the therapy's effectiveness and cost efficiency. If successful, this groundbreaking study could shift COPD management to prevention, reduce its global burden, and lay the foundation for future research and drug development.
-
A trial with healthy adult volunteers testing the effect of food on what happens to the drug emestedastat in the body
Expand descriptionEmestedastat was created to decrease the production of cortisol by the brain. This drug has been previously tested in nearly 400 people, including healthy adults and people with Alzheimer’s Disease and depression. The research project will test what the body does to emestedastat, such as how quickly it enters, moves through, and leaves the body. In particular, the research project will test if eating food has any effect on what happens to emestedastat in the body. If this and other clinical research projects are successful, the treatment being studied may be approved to treat people with Alzheimer’s Disease or depression in the future.
-
Isolated Medication plus Physiotherapy Airway Clearance Therapy in Kids with Chronic Suppurative Lung Diseases: A Randomised Controlled Trial (IM+PACT Kids: RCT)
Expand descriptionIn children, protracted bacterial bronchitis (PBB) and chronic suppurative lung disease (CSLD) represent chronic respiratory diseases on an overlapping continuum that can progress to irreversible bronchiectasis. In many children, early management, principally through appropriate antibiotic treatment can prevent progression of disease. Airway clearance techniques (ACT), prescribed by a physiotherapist are used routinely in children with chronic respiratory disease, such as cystic fibrosis and bronchiectasis to aid in sputum removal and have been shown to improve health outcomes and mortality. Increasingly, these techniques are being used in children with PBB/CSLD. However, there is no current evidence, in this cohort, to support the addition of airway clearance techniques to standard care (antibiotic therapy). Further the burden of care, particularly in undertaking airway clearance in this cohort is not well understood. Therefore, the aim of this study is to determine if airway clearance, as an adjunct to antibiotic therapy is efficacious in children with PBB/CSLD. That is, does the addition of airway clearance to standard care reduce the length of the exacerbation? We will also determine the burden of care and therapy for parents/carers of children with PBB/CSLD. Our study is a multi-site randomised controlled, parallel clinical trial with a qualitative component. Participants will be randomised to standard care (antibiotic therapy) or standard care plus airway clearance during exacerbations for 28 days regardless of cough resolution. The primary outcome will be the proportion of children with cough resolution by day-10. Secondary outcomes will be change in (measured via parent-proxy cough-related Quality of Life) PC-QoL scores from day-1 to day-10, 21 and 28 (post commencement of antibiotic therapy), and time to next exacerbation and change in and lung clearance index (LCI) from day-1 to one month and at 12-months. We hypothesise that the addition of airway clearance will result in a greater proportion of children with cough-resolution at day-10, improved PC-QoL, and longer time to next exacerbation. Burden of care for parents/carers of children with PBB/CSLD will be investigated, including the burden of therapy in those parents who undertake airway clearance therapy.
-
Improving outcomes for patients with blunt chest injuries by Boosting Regional Anaesthesia and Virtual Enhanced Chest Injury Pathway
Expand descriptionThe “BRAVE-CHIP” pathway is a novel, multidisciplinary model of care designed to accelerate the transition of patients with rib fractures into virtual care through a combination of contemporary rib fracture management and the early utilisation of regional anaesthesia, via a serratus anterior plane block placed in the ED. The project aim is to study the introduction the “BRAVE-CHIP” pathway into Royal North Shore Hospital by assessing whether it can have an impact on hospital length of stay whilst preserving pain management and respiratory function for our patients with rib fractures.
-
STARFAST: Study of Traumatic Brain Injury (TBI)/ Concussions in Australian-Rules Footballers receiving AST-004.
Expand descriptionThe study aims to evaluate the safety and efficacy signals of AST 004 as an acute intervention in athletes who sustain a sports related concussion during match play on game day. Adverse events, blood protein biomarker improvement, and clinical improvement will be analysed and neuropsychological testing assessed.
-
Evaluating the feasibility, acceptability, and preliminary efficacy of a peer support program for trans people on a waitlist to access gender affirming care (‘Thriving Transitions’): a randomised controlled trial
Expand descriptionThis study will conduct a randomised controlled trial to evaluate the feasibility, acceptability, and preliminary efficacy of the program to reduce suicidality, depressive symptoms, and improve quality of life, among trans people on a waitlist for initiating GAHT. Participants in the intervention condition will attend 7 x 1.5hr weekly sessions of the peer support program over seven weeks, co-facilitated by two trans people. Participants in the control group will remain on the standard care waitlist and will not receive the intervention. Participants in both groups will be required to complete 3 x 20min online health surveys. If proven feasible, acceptable, with preliminary evidence of efficacy, this program may represent an implementation-ready and readily scalable solution to address the mental health support needs of trans people on GAHT waitlists across Australia.
-
Evaluating an accessible dietary fibre intervention on overall side effect burden in people with breast cancer
Expand descriptionThis study aims to determine the tolerability, safety and efficacy of fibre supplementation to reduce side effect symptom severity and promote maintenance therapy adherence in people with breast cancer Who is it for? You may be eligible to join this study if you are aged 18 years or older, currently receiving systemic maintenance therapy (including chemotherapy, endocrine therapy and/or targeted therapy) for breast cancer, at 6 to 18 months following initial diagnosis, experience side effects to your maintenance therapy and are able to provide informed consent to all trial related procedures. Study details All participants who meet the eligibility criteria in this study will be randomised to either the intervention or control group. In the intervention group, all participants will be provided with a fibre supplement daily for 3 months, whilst on maintenance therapy for breast cancer. The control will continue with their current maintenance therapy and standard care. They will be offered the fibre supplement 1 month after the intervention has been completed. During and post intervention, participants will be assessed for side effects, dose modification, adverse events, gut microbiota, and brain structure. It is hoped that this research project will provide the first evidence supporting the beneficial role of fibre in reducing breast cancer treatment side effects, informing larger scale trials to produce the knowledge required for clinical implementation of fibre as a supportive cancer care strategy.
-
Effect of Brief Breathwork practice on stress via telehealth: feasibility and efficacy of online breathwork for five minutes a day for 30 days
Expand descriptionThe study is designed to reflect a real-world scenario where an exercise physiologist may deliver small group breathwork sessions online whilst providing participants materials to perform self-directed practice at home. Additionally, the study will begin the process of developing protocols for safe and effective telehealth breathwork sessions. This includes screening, orientating participants to the telehealth environment, providing technical support, setting online group class etiquette and structure, optimising the home practice environment, promoting social engagement support, and providing opportunities for feedback. The research will be used to inform future studies